Humatech (HUMT) Stock Price

Humatech Price

🇺🇸OTC·CLOSED
0.00USD
Market closed
Today +/-
+null USD
Today %
+null %
PRO

Humatech stock price

Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Humatech over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Humatech stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Humatech's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Humatech Stock Price History
DateHumatech Price
2/16/20260.00 USD
2/9/20260.00 USD

Humatech Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2001
195,000 USD
-930,000 USD
-976,000 USD
Jan 1, 2002
169,000 USD
-2.78 M USD
-2.79 M USD
Jan 1, 2003
241,000 USD
-2.19 M USD
-2.2 M USD
Jan 1, 2004
276,000 USD
-1.63 M USD
-1.88 M USD
Jan 1, 2005
721,000 USD
-895,000 USD
-1.03 M USD
Jan 1, 2006
1.57 M USD
-485,000 USD
-701,000 USD

Humatech Income Statement, Balance Sheet, Cash Flow Statement

Last updated Mar 3, 2026, 12:47 PM
 
REVENUE (k USD)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M USD)
NET INCOME (M USD)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
200120022003200420052006
000001,000
-
000000
0-2-2-1-10
-50.00
9.5713.0116.5223.0231.9134.28
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Humatech generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Humatech retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Humatech's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Humatech has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Humatech's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

 
ASSETS
CASH BALANCE (k USD)
RECEIVABLES (k USD)
OTHER REC. (M USD)
INVENTORIES (k USD)
OTHER CURRENT LIAB. (k USD)
CURRENT ASSETS (k USD)
TANGIBLE ASSETS (k USD)
LONG-T. INVEST. (M USD)
LONG-T. REC. (k USD)
INTANGIBLE ASSETS (M USD)
GOODWILL (M USD)
OTHER NON-CURRENT ASSETS (k USD)
NON-CURRENT ASSETS (k USD)
TOTAL ASSETS (k USD)
LIABILITIES
COMMON STOCK (M USD)
ADDITIONAL PAID-IN CAPITAL (M USD)
RETAINED EARNINGS (M USD)
OTHER EQUITY (M USD)
UNREAL. GAINS/LOSSES (M USD)
EQUITY (M USD)
LIABILITIES (k USD)
PROVISIONS (M USD)
OTHER SHORT-TERM LIAB. (M USD)
SHORT-TERM DEBTS (k USD)
LONG-TERM DEBT PORTION (k USD)
SHORT-TERM REC. (M USD)
LONG-T. LIAB. (M USD)
DEFERRED TAXES (M USD)
OTHER LIAB. (M USD)
LONG-T. LIABILITIES (M USD)
DEBT (M USD)
TOTAL CAPITAL (k USD)
199819992000200120022003200420052006
         
100300442071034
10103707231441739109
000000000
10090150161995241317
00000111224
1201005502331743046054184
70110270259144115146247172
000000000
00017600000
000000000
000000000
0003021000
70110270465146116146247172
190210820698320420206301356
         
0.120.120.121.353.655.467.718.318.48
00000.641.081.391.641.67
-0.73-1.14-1.47-2.44-5.8-8-9.88-10.91-11.61
000000000
000000000
-0.61-1.02-1.35-1.09-1.52-1.46-0.78-0.97-1.46
809080166104123213327527
00001.091.110.190.10.15
0.430.660.931.110.10.120.050.410.47
13014090650000285
00003483525600
0.640.891.11.341.641.70.520.841.43
0.150.321.060.450.20.180.470.430.38
000000000
000000000
0.150.321.060.450.20.180.470.430.38
0.791.212.161.791.841.880.991.271.81
180190810698320417206301353
Details

Balance Sheet

What Is the Balance Sheet?

The balance sheet is a financial snapshot of Humatech at a specific point in time. It follows the fundamental equation: Assets = Liabilities + Shareholders' Equity. Unlike the income statement (which covers a period), the balance sheet tells you what the company owns, what it owes, and what belongs to shareholders at a given date.

Assets

Current assets (cash, receivables, inventory) can be converted to cash within 12 months and indicate short-term liquidity. Non-current assets (property, equipment, intangible assets, goodwill) represent long-term investments. A high proportion of cash and short-term investments gives Humatech financial flexibility to weather downturns, fund acquisitions, or return capital to shareholders.

Liabilities

Current liabilities (accounts payable, short-term debt) are obligations due within one year. Non-current liabilities (long-term debt, pension obligations) are due further out. Key ratio to watch: the debt-to-equity ratio (Total Debt ÷ Shareholders' Equity). A ratio below 1.0 is generally healthy, meaning the company is funded more by equity than debt. Highly leveraged companies amplify both gains and losses.

Shareholders' Equity

Equity is the residual value belonging to shareholders after all debts are paid. It includes retained earnings (accumulated profits not paid out as dividends) and paid-in capital. Rising equity year over year is a positive sign — it means Humatech is building book value. Declining equity, especially when driven by losses or heavy share buybacks funded by debt, warrants closer scrutiny.

Key Ratios to Derive

From the balance sheet, you can calculate the current ratio (current assets ÷ current liabilities; above 1.5 is comfortable), book value per share (equity ÷ shares outstanding), and return on equity (net income ÷ equity; above 15 % is strong). Tracking these ratios over time reveals whether Humatech is strengthening or weakening its financial position.

 
NET INCOME (M USD)
DEPRECIATION (M USD)
DEFERRED TAXES (M USD)
CHANGES IN WORKING CAPITAL (M USD)
NON-CASH ITEM (k USD)
PAID INTEREST (M USD)
PAID TAXES (M USD)
NET CASH FLOW FROM OPERATING ACTIVITIES (M USD)
CAPITAL EXPENDITURES (M USD)
CASH FLOW FROM INVESTING ACTIVITIES (M USD)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M USD)
INTEREST INCOME AND EXPENSES (M USD)
NET DEBT CHANGE (M USD)
NET CHANGE IN EQUITY (k USD)
CASH FLOW FROM FINANCING ACTIVITIES (k USD)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (USD)
TOTAL DIVIDENDS PAID (M USD)
NET CHANGE IN CASH FLOW (M USD)
FREE CASH FLOW (M USD)
SHARE-BASED COMPENSATION (M USD)
199819992000200120022003200420052006
0000-2-2-1-10
000000000
000000000
000000000
00001,0001,000000
000000000
000000000
0000-10000
000000000
000000000
000000000
000000000
000000000
00001,0000000
00001,0001,000000
---------
000000000
000000000
0.01-0.17-0.49-0.32-1.13-0.92-0.61-0.35-0.03
000000000

Unlock the full history with 30+ years of data and forecast estimates.

Unlock all data — PRO

Humatech Stock Quarterly Figures

 
REVENUE (M USD)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M USD)
NET INCOME (M USD)
NET INCOME GROWTH (%)
SHARES (M)
2006 Q12006 Q22006 Q32006 Q42007 Q1
00000
00000
00000
34.0134.1234.334.6636.35
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Humatech generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Humatech retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Humatech's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Humatech has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Humatech's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Unlock the full history with 30+ years of data and forecast estimates.

Unlock all data — PRO

Humatech stock margins

The Humatech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Humatech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Humatech.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2001
-13.85 %
-476.92 %
-500.51 %
Jan 1, 2002
-48.52 %
-1,645.56 %
-1,653.25 %
Jan 1, 2003
-3.32 %
-908.71 %
-912.03 %
Jan 1, 2004
-14.13 %
-591.67 %
-680.8 %
Jan 1, 2005
27.18 %
-124.13 %
-143 %
Jan 1, 2006
31.77 %
-30.81 %
-44.54 %

Humatech Stock Sales Revenue, EBIT, Earnings per Share

The Humatech earnings per share therefore indicates how much revenue Humatech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Date
Sales per Share
EBIT per share
Earnings per Share
Jan 1, 2001
0.02 USD
-0.1 USD
-0.1 USD
Jan 1, 2002
0.01 USD
-0.21 USD
-0.21 USD
Jan 1, 2003
0.01 USD
-0.13 USD
-0.13 USD
Jan 1, 2004
0.01 USD
-0.07 USD
-0.08 USD
Jan 1, 2005
0.02 USD
-0.03 USD
-0.03 USD
Jan 1, 2006
0.05 USD
-0.01 USD
-0.02 USD

Humatech business model

Humatech Inc is an international company that specializes in the development, production, and marketing of products for the healthcare industry. The company was founded in 1983 and has since adapted its business models and strategies to meet the changing demands of the market. It is now headquartered in Virginia, USA and operates on multiple continents. The business model of Humatech Inc focuses on the manufacturing of diagnostic and testing products for laboratory and clinical facilities. These products are designed for the diagnosis of diseases such as cancer, diabetes, pregnancy, thyroid problems, and many others. The company also offers HIV, hepatitis, and troponin tests. The high quality of these products has helped the company establish strong brand recognition and customer loyalty. In addition to its products, Humatech Inc also provides services in various areas to offer comprehensive solutions tailored to individual needs. These services include consulting, software solutions, and training, contributing to optimized and efficient operations in medical facilities and laboratories. The different divisions of Humatech Inc encompass a wide range of products and services. The category of diagnostic and testing products forms the core of the company, including tests for diabetes, pregnancy, thyroid problems, cancer, HIV, and hepatitis. The range also includes specialized tests for kidney problems and heart diseases. The company is constantly striving to expand its range of tests for new health issues. Under the category of consulting services, Humatech Inc offers in-depth knowledge of current medical developments, diagnostic procedures, and testing methods. Customers can choose from a wide range of services, including the development of specific test procedures, marketing support, and workflow optimization. The "software solutions" business field includes a variety of online tools to support diagnostic procedures and tests. The software allows medical facilities and laboratories to automate their workflow, manage and analyze data, and quickly retrieve test results. To provide customers with added value, Humatech Inc also offers a range of training programs. These not only cover the operation and application of the products, but also teach optimal work and result processes. Overall, Humatech Inc is an important player in the healthcare industry. By focusing on the development and marketing of diagnostic and testing products, the company is able to sustainably convince its customers through high product quality and services. The wide product range, services, and extensive network of employees, consultants, and customers make the company a forward-thinking service provider.

Humatech SWOT Analysis

Strengths

Humatech Inc has built a strong reputation in the industry over the years, gaining the trust and loyalty of customers.

With a diverse range of innovative products, Humatech Inc remains competitive and meets the evolving needs of the market.

Humatech Inc invests heavily in research and development, allowing them to stay at the forefront of technology advancements and maintain a competitive advantage.

Weaknesses

Although Humatech Inc has a strong presence in its domestic market, it lacks significant global reach, potentially limiting growth opportunities.

Humatech Inc relies heavily on a few key suppliers, which exposes them to risks such as supply disruptions and potential price fluctuations.

The extensive investments in research and development impose significant costs on Humatech Inc, affecting profitability in the short term.

Opportunities

Humatech Inc can expand its market presence by targeting emerging markets with growing demand for their products.

Collaborating with strategic partners can help Humatech Inc access new technologies, markets, and resources, driving further growth and innovation.

With increasing environmental concerns, Humatech Inc can capitalize on the growing demand for sustainable solutions and align their products accordingly.

Threats

The industry is highly competitive, with several players vying for market share, which can pose challenges for Humatech Inc's growth and profitability.

Stringent regulations and compliance requirements in the industry may limit Humatech Inc's operations or increase costs.

Fluctuations in the global economy and financial markets can impact customer spending and demand for Humatech Inc's products.

Humatech Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Humatech historical P/E ratio, EBIT multiple, and P/S ratio

Humatech shares outstanding

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2001
9.57 M Aktien
Jan 1, 2002
13.01 M Aktien
Jan 1, 2003
16.52 M Aktien
Jan 1, 2004
23.02 M Aktien
Jan 1, 2005
31.91 M Aktien
Jan 1, 2006
34.28 M Aktien
Unfortunately, there are currently no price targets and forecasts available for Humatech.

Humatech shareholders

% Name
%
Quad-Cities Investment Group, LLC
Quad-Cities Investment Group, LLC

Humatech Executives and Management Board

DW

David Williams

(59)

President, Chief Executive Officer, Director

Compensation190,540 USD
JR

John Rottweiler

(63)

Chief Financial Officer, Secretary, Director

Compensation125,000 USD

Humatech Research

Soon

Deep-dive analyses, investment theses, and proprietary research — curated by Eulerpool.

Research reports are coming soon

We're building institutional-grade equity research for Humatech and thousands of other companies.

Most common questions regarding Humatech

The business model of Humatech Inc revolves around the manufacturing and distribution of innovative medical devices for the healthcare industry. Humatech Inc specializes in developing cutting-edge technologies that cater to various medical needs, ensuring sustainable solutions for patients and healthcare providers globally. With a strong focus on research and development, the company aims to improve patient outcomes and enhance medical procedures. By consistently delivering high-quality products and maintaining strong relationships with healthcare professionals, Humatech Inc continues to thrive in the competitive healthcare market.

All fundamentals about Humatech

Our stock analysis for Humatech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Humatech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.